Geron, GE Healthcare in stem cell deal - The Business Review (Albany):

milicinodijoo1981.blogspot.com
they will collaborate to develop and commercializr cellular assay products derived from humanb embryonicstem cells. Chalfont St. England-based GE Healthcare (NYSE: GE) and Menlo Calif.-based Geron (Nasdaq: GERN) did not disclosd financial terms ofthe deal. “In GE Healthcarre we have found the ideal partner with whom to developthis near-terkm commercial opportunity," said David J. Geron’s senior vice presidenyt of business development and chiefpatent counsel.
"There is much anticipationn of the availability ofhESC [human embryonic stem cells]-derivedd cells for drug discovery applications within the pharmaceutical industry and we look forward to working closely with GE Healthcar to deliver these promising products.” Under the terms of the GE Healthcare has been granted an exclusive license unde Geron’s extensive intellectual property portfolii covering the growth and differentiation of human embryonivc stem cells, as well as a sublicensew under Geron’s rights to the foundational hESC patents held by the .
GE Healthcarse and Geron have establisheda multi-yearf alliance program under which scientistsw from the two companies will work closelyh together to develop human embryonic stem cell-based products for drug The program will use stem cellds derived from lines listed on the Humajn Pluripotent Stem Cell Registry. GE Healthcare will fund the reseach and development program and will be responsible for sales and distribution of products developed under the Under the terms ofthe agreement, intellectuall property rights arising from the alliance program researcn will be shared, with GE Healthcar e receiving rights for the development of drug discovery and Geron receiving rights for cell therapy GE Healthcare conducts some of its researcuh at the in Niskayuna, a suburbn of Schenectady.
And earlier this GE Healthcare openeda $165 million mammographgy equipment production facility in the Rensselaer Technologg Park.